Repeat screening for HIV: When to test and why

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 4, 2000, Pages 339-345

  Kaplan, Edward H ^a   Satten, Glen A ^b  

^a YALE SCHOOL OF MANAGEMENT   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cost benefit analysis; HIV prevalence; HIV screening; Mathematical model; Repeat screening

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LABORATORY DIAGNOSIS; MASS SCREENING; MATHEMATICAL MODEL; PRIORITY JOURNAL;

EID: 0034176215     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200004010-00010     Document Type: Article

References (19)

1. Albert AE, Warner DL, Hatcher RA, Trussel J, Bennett C. Condom use among female commercial sex workers in Nevada's legal brothels. Am J Public Health 1995;85:1514-20.
2. Pyett PM, Haste BR, Snow J. Risk practices for HIV infection and other STDs amongst female prostitutes working in legalized brothels. AIDS Care 1996;8:85-94.
3. Goh CL, Chan RK. Prevalence of sexually transmitted diseases among commercial sex workers in Singapore from 1977 to 1993: the effects of screening measures. Ann Acad Med Singapore 1995; 24:500-4.
4. Brown AE, Tomlinson JP, Brundage JF, Burke DS. The U.S. army HIV testing program: the first decade. Mil Med 1996;161:117-22.
5. Tramont EC, Burke DS. AIDS HIV in the United States military. Vaccine 1993;11:529-33.
6. Brandeau ML, Owens DK, Sox CH, Wachter RM. Screening women of child-bearing age for human immunodeficiency virus: a model-based policy analysis. Manage Sci 1993;39:72-92.
7. Paltiel AD, Kaplan EH. The cost-effectiveness of HIV testing: accounting for differential participation rates. Med Decis Making 1997;17:490-5.
8. Lee HL, Pierskalla WP. Mass screening models for contagious diseases with no latent period. Oper Res 1988;36:917-28.
9. Zelen M. Optimal scheduling of examinations for the early detection of disease. Biometrika 1993;80:279-93.
10. Nevada Administrative Code, 441A.800, 1997 (retrieved via the Internet at http://www.Ieg.state.nev.us/NAC/Index.htm on April 12, 1999).
11. Parliament of Victoria [New South Wales, Australia]. Prostitution Control Act 1994 (retrieved via the internet at http:// www.dms.dpc.vic.gov.au/12d/P/ACT01120/3_2.html on April 12, 1999).
12. Active Military Duty Personnel, 1940-1997, Department of Defense (retrieved via the internet at http://couponsurfer. infoplease.com/ipa/A0004598.html on July 7, 1999).
13. Peterson LR, Satten GA, Dodd R, Busch M, Kleinman S, Grindon A, Lenes B, and the HIV Seroconversion Study Group. Duration of time from onset of human immunodeficiency virus type 1 infec tiousness to development of detectable antibody. Transfusion 1995:34:283-9.
14. Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serological markers preceding HIV-1 seroconversion: implications for blood and tissue donor screening. Transfusion 1995;35:91-7.
15. United States General Accounting Office. Blood plasma safety: plasma product risks are low if good manufacturing practices are followed. General Accounting Office Report GAO/HEHS-98-205. Washington, DC: U.S. General Accounting Office, 1998.
16. Mausner JS, Kramer S. Epidemiology: an introductory text. Philadelphia: WB Saunders, 1985.
17. Weber JT, Reich RR, Horsley R, Todd RL. Absence of HIV seroconversion among sex workers at legal brothels, Nevada, 1990-95 (unpublished).
18. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16: 54-62.
19. AuBuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 1997;37:45-51.